CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Wednesday, June 9, 2010 - 15:40
in Health & Medicine
DURHAM, N.C., June 9 — CoLucid Pharmaceuticals, Inc., (“CoLucid”), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced...